Follow-up of Patients Who Received Palliative Lung Radiotherapy: A Single Center Experience

Aim: Lung cancer (LC) is the most common among malignant tumors. Cure is not possible in patients with stage-4. These patients receive palliative radiotherapy (RT), chemotherapy and supportive care. This study aims to examine the relationship between survival time and some biochemical features in stage-4 patients who received palliative RT to their lungs. Methods: 51 patients who applied to our hospital for palliative RT to their lungs between July 2016 and May 2022 were included in the study. All patients; age, survival rate, gender and type of carcinoma [non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)]; alanine aminotransferase, aspartate amino transferase, sodium, potassium, hematocrit, hemoglobin, lymphocyte, neutrophil, platelet, urea and lactate dehydrogenase values were measured. Correlation coefficients along with descriptive statistics were computed for these features. Resuls: All patients have stage-4 LC. 13 (25.49%) patients are female and 38 (74.50%) patients are male. NSCLC had 41(80.39%) of all patients, SCLC pathology had 10 (19.60%) of all patients.All patients received palliative RT to their lungs. While the median survival time for patients diagnosed with NSCLC was 18 weeks, the median survival time for patients with SCLC pathology was found 4 weeks. Conclusion:The overall survival time for both groups was found 16 weeks. Relationships between survival time and some biochemical properties were determined in patients with stage-4 LC who received palliative RT to the lungs. Survival time in NSCLC group patients was found to be approximately 4 times higher than in SCLC group patients.